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Myeloid differential primary response protein (MyD88) is a critical component in the signaling cascade through Toll-like receptors
(TLRs) and is induced by a interferon (IFN-a). To examine the role of MyD88 in the antiviral activity of IFN-a against hepatitis B virus
(HBV), we established MyD88 stably expressing cell lines and studied HBV replication in these lines after transient transfection. The levels
of HBV proteins and viral replicative intermediates were effectively reduced in MyD88-expressing cells. A significant reduction of total and
cytoplasmic viral RNAs in MyD88 stably expressing cells was also observed. Using a nuclear factor-nB (NF-nB) dependent reporter assay, it
was shown that activation of NF-nB was moderately increased in the presence of expression of MyD88, and further significantly increased by
co-expression of HBV. These results suggest a novel mechanism for the inhibition of HBV replication by IFN-a via expression of MyD88
protein involving activation of NF-nB signaling pathway and downregulation of viral transcription.
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factor-nBIntroduction
Infection of hepatitis B Virus (HBV) continues to be a
significant global health problem. It is estimated that there
are approximately 350 million chronic HBV carriers world-
wide, and chronic infection carries a significant risk of liver
cirrhosis and hepatocellular carcinoma that has a high
mortality rate (reviewed by Kao and Chen, 2002; Tiollais
et al., 1985). In the past two decades, a interferon (IFN-a)
has been proven effective in the treatment of chronic
hepatitis B patients (Carreno et al., 1992; Yuen et al.,
2001). However, the antiviral mechanism of IFN-a and the
biological function of many IFN-a responsive genes have
not been fully elucidated.
To study the global effect of IFN-a on cellular genes and
its interaction with HBV, we used cDNA microarray filters
dotted with 14000 human genes to analyze transcriptional
changes between an HBV DNA transfected hepatoblastoma0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.cell line (HepG2.2.15) and its parental cell line (HepG2) pre-
and post-IFN-a treatment. Analysis of gene profiles revealed
that the mRNA expression level of myeloid differential
primary response protein MyD88 (MyD88) was reduced in
the HBV persistently infected HepG2.2.15 cells compared
with HepG2 cells, and this could not be restored by the
treatment with IFN-a. This result suggested that the expres-
sion of MyD88 was inhibited by HBV, and the interplay
between MyD88 and HBV might account for the establish-
ment of viral persistence. This also suggested that MyD88
protein could play an important role in antiviral activity
against HBV.
MyD88 was discovered as a primary response gene in
mouse myeloid cells (M1 cells) (Lord et al., 1990). Func-
tional studies have shown that MyD88 protein is a critical
component in the signaling cascade of the innate immune
response through Toll-like receptors (TLRs) that participate
in the recognition of pathogen-related molecules, which are
shared by large groups ofmicroorganisms. For example, Toll-
like receptor 4 (TLR 4) recognizes bacterial lipopolysaccha-
ride (LPS), and Toll-like receptor 9 (TLR 9) recognizes
bacterial CpG DNA (Arbour et al., 2000; reviewed by Bauer
and Wagner, 2002; Hemmi et al., 2000, 2003). MyD88
protein also participates in the signaling pathway mediated
by interleukin-1 (IL-1) receptors as well as interleukin-18
receptors (Adachi et al., 1998). Activation of these membrane
Fig. 1. Kinetics of IFN-a induced expression of MyD88 gene in HepG2
cells. HepG2 cells (3  106) were treated with 1000 IU/ml IFN-a for the
indicated time periods (A, C) or treated with indicated dose of IFN-a for 6 h
(B, D). Quantitative real-time PCR was performed to detect the relative
levels of MyD88 mRNA and GAPDH mRNA (A, B). Western blot analysis
was carried out to detect the expression of MyD88 protein using anti-
MyD88 antibody. The level of total protein in cell lysates was monitored by
anti-actin antibody (C, D). Blots were quantified by densitometry and
normalized to the corresponding actin bands. The relative values of MyD88
protein expression were shown at the bottom.
Fig. 2. Establishment of stable cell clones expressing MyD88 protein. (A)
Detection of MyD88 protein expression in stably transfected HepG2 cells.
Western blot was used to analyze the expression of MyD88 protein in cell
lysates from neomycin-resistant HepG2 clones untreated (Neo) or treated
with 1000 IU/ml IFN-a for 6 h (Neo + IFN), and from two MyD88-
expressing clones (MyD88-8 and MyD88-6) using anti-MyD88 antibody.
The level of total protein in cell lysates was detected by anti-actin antibody.
(B) The cell growth curves of the Neo and MyD88 clones (MyD88-6 and
MyD88-8). Cells (5  105) were seeded onto 60-mm dishes, then
trypsinized and counted daily. Standard errors showed the results of two
independent experiments performed in duplicate.
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with MyD88 protein by a homophilic interaction between
their Toll receptor-interleukin-1 receptor (TIR) domains. This
subsequently leads to the activation of IL-1 receptor-associ-
ated kinase (IRAK) by the death domain of MyD88
(reviewed by Akira et al., 2001). However, the association
between MyD88 and IFN-induced signaling pathway, and a
possible antiviral role of MyD88 protein, are not clear.
In this study, we investigated whether the interferon-
inducible protein MyD88 has antiviral activity against HBV
replication, and the mechanism of such activity. We estab-
lished HepG2 cell lines stably expressing MyD88 protein
and transiently transfected them with HBV replicative
plasmids. Our experiments demonstrated that the levels ofHBV proteins, replicative intermediates, and viral RNA
transcripts were all reduced in MyD88-expressing clones.
Furthermore, we found that nuclear factor-nB (NF-nB) was
activated by HBV replication and this HBV-induced activa-
tion was strongly enhanced in MyD88-expressing cells.
These findings suggest a novel mechanism for the inhibition
of HBV replication by IFN-a via expression of MyD88,
involving activation of the NF-nB signaling pathway and
possibly downregulation of viral transcription.Results
Kinetics of IFN-a induced expression of MyD88 gene in
HepG2 cells
To analyze the kinetics of IFN-a induced expression of
MyD88 gene, HepG2 cells were treated with 1000 IU/ml
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expression of MyD88 were analyzed by quantitative real-
time PCR and Western blot analysis separately. In untreated
cells, MyD88 gene transcription and protein expression was
detected at a baseline level, which increased about twofold
by 3–6 h following IFN-a treatment and then dropped again
to baseline level by 12 h (Figs. 1A, C). The transcription and
protein expression of MyD88 in HepG2 cells was dose-
dependent, because increasing dose of IFN-a led to increas-
ing expression of MyD88 gene after IFN-a treatment for 6
h with a maximal response occurring at 2000 IU/ml IFN-a
(Figs. 1B, D). This experiment confirmed that the expres-
sion of MyD88 could be induced by IFN-a and was
increased during the first 6 h after the treatment of IFN-a.
Establishment of MyD88-expressing cell line
MyD88-expressing clones were established by transfect-
ing the human hepatoblastoma cell line HepG2 with a
MyD88 eukaryotic expression plasmid including a G418-
resistant marker. After selection with G418, two MyD88Fig. 3. Reduction of HBV protein synthesis in MyD88-expressing clones. MyD8
(Neo + IFN) or without (Neo) IFN treatment were transiently transfected with pH
After transfection for 1 (1d), 2 (2d) or 3 days (3d), culture supernatants (A) and ce
HBeAg by the standard immunoassay. The activity of chloramphenicol acetyltra
transfection efficiency. The values were calculated as percentages of the value for
three independent experiments performed in duplicate.positive clones (MyD88-6 and MyD88-8) were isolated, and
a further clone (Neo) expressing the neomycin-resistant gene
only was selected as a negative control. The expression of
MyD88 in these two MyD88 positive clones and in the Neo
clone with or without IFN-a treatment was quantitated by
Western blot analysis using anti-MyD88 antibody. The
expression of MyD88 in these two MyD88 positive clones
was slightly higher than in the IFN-a-treated Neo clone (Fig.
2A). The influence of MyD88 protein on cell growth was
also assessed. As shown in Fig. 2B, there was no apparent
effect of MyD88 expression on the growth rate of MyD88-6
and MyD88-8 clones when compared with Neo clone.
MyD88 protein reduces the synthesis of HBV surface and e
antigens
To examine the effect of MyD88 on the synthesis of
HBV proteins, the three clones (Neo, MyD88-6, and
MyD88-8) were transiently transfected with the pHBV3.8
plasmid. At time point of 1, 2, or 3 days after transfection,
supernatants were collected and assayed for HBV surface8 clones (MyD88-6 and MyD88-8) and the neomycin-resistant clone with
BV3.8 and pcDNA-CAT plasmids as described in Materials and methods.
ll lysates (B) were collected and analyzed for the expression of HBsAg and
nsferase (CAT) in cell lysates was assessed by CAT ELISA to normalize
the HBV transfected Neo clone and shown as the mean F standard error of
Fig. 4. MyD88 efficiently inhibits HBV replication. MyD88 clones
(MyD88-6 and MyD88-8) and the neomycin-resistant clone untreated
(Neo) or treated with IFN-a (Neo + IFN) were transiently co-transfected
with the pHBV3.8 and pcDNA-CAT plasmids. Cells were harvested 48 h
after transfection. HBV replicative intermediates DNAwere extracted from
core particles and analyzed by Southern blot. The HBV DNA was loaded
onto 1.0% agarose gel according to the transfection efficiency measured by
CAT ELISA, electrophoresed, and then transferred to nylon membranes.
For hybridization, full-length HBV DNA probes labeled with [a-32P] dCTP
were used. The relaxed circular (RC), double-stranded linear (DS), and
single-stranded linear (SS) HBV DNA forms were indicated. Quantification
of three independent experiments was obtained by densitometry and is
shown at the bottom. Data were normalized to those from HBV transfected
Neo clone.
Fig. 5. Inhibition of HBV total and cytoplasmic RNAs by MyD88 protein.
MyD88 clones (MyD88-6 and MyD88-8) and the neomycin-resistant clone
untreated (Neo) or treated with IFN-a (Neo + IFN) were transiently co-
transfected with the pHBV3.8 and pcDNA-CAT plasmids. Total (A) and
cytoplasmic (B) RNAs were extracted 48 h after transfection and analyzed
by Northern blot using [a-32P] dCTP-labeled full-length HBV DNA probes.
The blots were stripped and rehybridized with [a-32P] dCTP-labeled h-
actin probes to control for gel loading. The arrows indicated the location of
the 3.5-, 2.4-, and 2.1-kb viral RNA bands. Quantification of three
independent experiments was obtained by densitometry and is shown at the
bottom. Data were normalized to the level of corresponding h-actin band
and those obtained with HBV transfected Neo clone.
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munoassay. Compared to the Neo clone, the secretion of both
HBsAg and HBeAg was reduced in the MyD88-6 clone by
about 60% for HBsAg and HBeAg, and in the MyD88-
8 clone by about 35% for HBsAg and 30% for HBeAg (Fig.
3A). IFN treatment of the Neo clone led to a reduction of
about 20% for HBsAg and 15% for HBeAg compared to the
untreated Neo clone (Fig. 3A). Next, cell lysates were
analyzed for the intracellular accumulation of viral proteins
3 days post-transfection. The level of intracellular HBsAg
was reduced by about 55% in MyD88-6, 30% in MyD88-8,
and 15% in the IFN-treated Neo clone (Fig. 3B). At the same
time, the reduction of intracellular HBeAg was about 40% in
MyD88-6, 15% in MyD88-8 and 10% in the IFN-treated
Neo clone (Fig. 3B). These results showed that the synthesis
of HBV proteins was markedly reduced in MyD88 positive
clones.
MyD88 protein reduces the synthesis of HBV replicative
intermediates
To investigate the influence of MyD88 protein on HBV
replication, the three clones were transfected with pHBV3.8
plasmid. Southern blot analysis of viral replicative inter-
mediates DNA extracted from core particles was performed
2 days after transfection. As shown in Fig. 4, the HBV
replicative forms were dramatically reduced by about 80%
in the MyD88 positive clones (MyD88-6 and MyD88-8)
and by about 30% in the IFN-a-treated Neo clone. Thus, in
addition to reducing the synthesis of viral proteins, the
expression of MyD88 protein also effectively reduced
HBV DNA replication.Both total and cytoplasmic HBV RNAs are reduced in
MyD88 clones
To investigate whether the reduction of HBV protein
synthesis and DNA replication was associated with the
reduction of viral RNA transcripts, Northern blot analysis
was used to examine the total and cytoplasmic HBV RNAs
in these three clones after transfection with pHBV3.8 for 2
days. A reduction of about 70% for total viral transcripts and
60% for cytoplasmic viral transcripts was observed in both
MyD88 clones (MyD88-6 and MyD88-8), although treat-
ment of the Neo clone with IFN-a resulted in a minor
reduction of total viral transcripts (by about 25%) and
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These results suggested that the reduced level of viral
proteins and DNA replicative intermediates in the MyD88
positive clones might be related to the inhibition of viral
RNA transcription.
Synergy of MyD88 protein and HBV replication in the
activation of NF-jB
MyD88 protein is an important adaptor in activation of
the NF-nB-dependent signaling cascade. A recent study has
demonstrated that HBV replication and viral capsid forma-
tion could be disrupted by strong activation of NF-nB
(Biermer et al., 2003). To investigate whether the reduced
levels of HBV products in MyD88 positive clones could be
associated with the activation of NF-nB, the NF-nB-depen-
dent luciferase reporter plasmid pNF-nB-Luc was co-trans-Fig. 6. Synergy between MyD88 protein and HBV replication in the activation
neomycin-resistant clone (Neo) were transiently transfected with pNF-nB-Luc
transiently transfected with pNF-nB-Luc, pHBV3.8 (V), pcDNA-MyD88 (MyD
indicated (B). In each transfection, pcDNA-CATwas added as internal control of tr
and HepG2 cells) were incubated with or without 1000 IU/ml IFN-a (IFN) for an
activity. The values of relative luciferase activity were presented by folding over
represent the average of three independent experiments performed in duplicate.fected with pHBV3.8 into Neo, MyD88-6, and MyD88-
8 clones, and the luciferase activity was measured. As
expected, MyD88 positive clones showed increased activa-
tion of NF-nB by about 2.0-fold, and HBV replication in the
Neo clone also increased the activation of NF-nB by about
1.5-fold. Unexpectedly, strong activation of NF-nB was
triggered (about six- to eightfold) in MyD88 positive clones
after transfection with replication-competent HBV DNA
(Fig. 6A). Similar results were also observed after transiently
co-transfecting HepG2 cells with pNF-nB-Luc, pHBV3.8,
and pcDNA-MyD88 (Fig. 6B). To identify the effect of HBV
proteins on the activation of NF-nB, pcDNA-HBx (encoding
HBV x protein) and pCI-neo/HBs (encoding HBV surface
protein) were co-transfected with pcDNA-MyD88, respec-
tively. Interestingly, although the activation of NF-nB by
HBx protein alone was higher than that by HBV replication,
co-expression of HBx protein and MyD88 protein in HepG2of NF-nB. MyD88-expressing clones (MyD88-6 and MyD88-8) and the
alone, or together with pHBV3.8 (V) (A). Similarly, HepG2 cells were
88), pcDNA-HBx (HBx), and pCI-neo/HBs (HBs), alone or together as
ansfection efficiency. After transfection for 18 h, the control cells (Neo clone
additional 6 h. All cultured cells were then lysed and assessed for luciferase
the value of pNF-nB-Luc transfected IFN-untreated control cells. Results
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that by HBVand MyD88 protein together (Fig. 6B). HBsAg
had no effect on NF-nB activation (Fig. 6B). In addition, a
moderate increase of NF-nB activation was also detected
after IFN-a treatment for 6 h (Figs. 6A, B). These results
suggest that there is a synergy between MyD88 protein and
HBV replication to activate NF-nB, which was independent
of HBx protein, and the reduction of HBV replication in
MyD88 positive clones may be mediated by strong activa-
tion of the NF-nB signaling pathway.Discussion
Although IFN-a has been used for treatment of HBV
infection for two decades, the antiviral mechanism of IFN-a
and the biological function of many IFN-a response genes
have not been fully elucidated. Studies have been undertak-
en to clarify its mechanism by using HBV transfected cell
lines or HBV transgenic mice.
With different cell lines, it has been shown that the
antiviral state induced by IFN-a is complex and can be
established by induction of a wide pattern of genes and
activation of a variety of cellular functional proteins (Der et
al., 1998; reviewed by Katze et al., 2002; reviewed by Sen,
2001). Some interferon-inducible proteins, such as the 2V,5V-
oligoadenylate synthetase (OAS), the double-stranded RNA
dependent protein kinase (PKR), and the Mx protein, which
are involved in intracellular antiviral response, are well
defined (Ronni et al., 1995, 1997; reviewed by Samuel,
2001). However, it has also been shown that the inhibition
of HBV replication by IFN-a is not limited to certain IFN-a-
inducible proteins. For example, although the IFN-a-induc-
ible human MxA protein, which has a well-known antiviral
activity against several RNA viruses, was reported to block
the replication of HBV at a posttranscriptional level in the
human hepatoma cell line Huh7 (Gordien et al., 2001), IFN-
a was recently found to suppress HBV replication in MxA-
deficient cells (Rang et al., 2002). It is hypothesized that
multiple proteins, including MxA and others, interact to
build up the IFN-a antiviral networks and determine the
level of HBV replication and transcription. In the present
study, by establishment of MyD88-expressing HepG2 cell
lines and transfecting them with HBV replication-competent
DNA, the inhibition of HBV replication by IFN-a inducible
MyD88 protein was demonstrated. Our results showed that
levels of HBV proteins, viral replicative intermediates, and
viral transcripts were all significantly reduced in two
MyD88 positive clones. Inhibition of HBV by MyD88
protein is consistent with the inhibitory effects of IFN-a/b
on HBV replication in cell lines and transgenic mice
(Cavanaugh et al., 1998; Guidotti et al., 1994, 1999; Guilhot
et al., 1993; Tsui et al., 1995; Uprichard et al., 2003). In our
study, the expression of MyD88 increased during the first 6
h after the treatment of IFN-a, and HBV replication was
reduced in MyD88 stably expressing clones. Taken together,our results indicate that MyD88 protein plays an important
role in antiviral response induced by IFN-a.
Many studies have demonstrated that MyD88 protein is a
key cytoplasmic adaptor in the signaling cascade of the
innate immune response through Toll-like receptors, which
results in the activation of NF-nB-dependent signal tran-
scription (Medzhitov et al., 1998; Wesche et al., 1997).
However, the association of MyD88 and activation of NF-
nB with IFN-induced antiviral activity has not been reported.
To study this possibility, an NF-nB-dependent reporter
plasmid was co-transfected with HBV replication-competent
DNA into MyD88-expressing cells. As our data shown, NF-
nB was modestly activated by either IFN-a treatment, HBV
replication, or expression of MyD88, but strongly activated
by HBV replication in MyD88-expressing cells (Figs. 6A,
B). As NF-nB activation has been shown to interfere with
HBV replication, these results suggest that the inhibition of
HBV replication by MyD88 may be mediated via activation
of NF-nB.
As a transcription factor, NF-nB plays a crucial role in
both innate and adaptive immunity by regulating the tran-
scription of multiple inflammatory and immune genes, such
as proinflammatory cytokines, chemokines, and adhesion
molecules (reviewed by Benedict et al., 2002; reviewed by
Hatada et al., 2000; reviewed by Li and Verma, 2002;
reviewed by Richmond, 2002). For a role of NF-nB in
antiviral activity, Biermer et al. (2003) have demonstrated
recently that the noncytopathic antiviral effect of tumor
necrosis factor a (TNF-a) could be blocked by inhibition
of NF-nB, and the strong intracellular upregulation of NF-
nB signaling pathway in the absence of TNF-a treatment
fully mimicked the antiviral effect of TNF-a. Our data
showed that strong activation of NF-nB by MyD88 and
HBV is also associated with significant inhibition of HBV
replication in the absence of treatment with IFN-a. Thus,
activation of NF-nB may be a common pathway in the innate
antiviral response to HBV, which may be independently
initiated by cytokines, such as IFN-a and TNF-a. Studies
are needed to identify the cellular genes that are affected by
both MyD88 and NF-nB and act to downregulate all HBV
transcripts simultaneously.
HBV x protein (HBx), as a small transcriptional regula-
tory protein essential for viral replication, has been shown to
activate several transcription factors including several mem-
bers of NF-nB family (Lucito and Schneider, 1992; Su and
Schneider, 1996; Su et al., 2001; Tai et al., 2000; Xu et al.,
2002). To study whether the synergy of HBVand MyD88 in
activation of NF-nB was due to the HBx, the activation of
NF-nB by HBx and MyD88 protein was determined. As
data shown, the activation of NF-nB by HBx protein was
higher than by HBV replication, but co-expression of HBx
protein and MyD88 protein in HepG2 cells could not
increase the activation of NF-nB higher than that by HBV
and MyD88 protein together (Fig. 6B). The results sug-
gested that HBx was not the crucial component of HBV to
be associated with MyD88 protein to activate NF-nB.
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investigated is the mechanism of the synergy between
MyD88 and HBV replication in activation of NF-nB.
HBV replication alone is not a strong activator of NF-nB,
neither is HBV x protein. MyD88 protein, as a cytoplasmic
adaptor, can associate with many proteins by homophilic
interaction. Studies are ongoing to investigate whether
MyD88 molecule can physically or functionally interact
with other HBV proteins to initiate the NF-nB-dependent
signal pathways.Materials and methods
Plasmids
The MyD88 gene (Genbank access number NM_002468)
was amplified by RT-PCR from the total RNA of HepG2
cells using sense primer (5VGGAATTCGTTATGGCTGCA-
GTTATGGCTGCAGGAGGTCCCG3V) and antisense prim-
er (5VTAAAGCGGCCGCTCAGGGCAGGGACAAGG-
C3V). This amplified segment was cloned into pET23a
(Novagen) and then inserted into EcoRI/NotI sites of the
eukaryotic expression plasmid pcDNA3.1/myc-His C (Invi-
trogen), under the control of the cytomegalovirus (CMV)
promoter. This plasmid was referred to as pcDNA-MyD88.
Plasmid pHBV3.8 encoding the whole transcript of HBV
DNA (adr subtype) from the core promoter to the polyA
signal region (nucleotides 1403–3215 and 1–1987) was
constructed as a 1.2 copy insert of the full-length HBV
genome into vector pBS+ (Stratagene) via restriction enzyme
EcoRI and PstI sites (kindly provided by Prof. Wang Yuan,
Institute of Biochemistry, Academia Sinica, Shanghai). After
transfection into HepG2 cells, the pHBV3.8 can express both
HBsAg and HBeAg, and can initiate HBV replication.
Plasmid pcDNA-HBx containing open read frame of HBx
protein and plasmid pcDNA-CAT containing the chloram-
phenicol acetyltransferase (CAT) gene under control of the
CMV promoter was constructed as describe above. The pCI-
neo/HBs plasmid was constructed by subcloning HBsAg
encoding gene into the EcoRI site of pCI-neo (Promega),
and the HBsAg was expressed under the control of the CMV
promoter. The NF-nB-dependent luciferase reporter plasmid
pNF-nB-Luc was purchased from Stratagene Corporation.
Cell culture and establishment of cell lines
HepG2 cells derived from human hepatoblastoma were
cultured in Dulbecco’s modified Eagles’ medium supple-
mented with 10% fetal calf serum and penicillin (100 IU/ml)
and streptomycin (100 Ag/ml) (Gibco/BRL). HepG2 cells
(1  106) were transfected with 8 Ag of either pcDNA3.1/
myc-His C or pcDNA-MyD88 using the calcium phosphate
precipitation method. Thirty-six hours after transfection, the
cells were split in a ratio of 1:4 and cultured in medium
containing 200 Ag/ml geneticin (G418 sulfate, Gibco/BRL).After culturing in selection medium for 3 weeks, the
individual neomycin-resistant clones were isolated. One
clone expressing the neomycin resistance gene (Neo) and
two clones expressing MyD88 (MyD88-6 and MyD88-8)
were selected for the further study.
Western blot analysis
Cell clones or HepG2 cells were treated with recombinant
human IFN-a (R&D systems) at the indicated dose and for
the indicated time periods, and then harvested. Equal quan-
tities of total protein from cell lysates were separated by 10%
SDS-PAGE gel electrophoresis and blotted electrophoreti-
cally to a nitrocellulose membrane (Roche). The membrane
was blocked with the phosphate-buffered saline (PBS) con-
taining 5% skim milk and then incubated overnight with
1:1000 anti-MyD88 antibody (Sigma) or 1:10000 anti-actin
antibody (Oncogene), washed three times in PBST (0.05%
Tween 20 in PBS), and then incubated with horseradish
peroxidase-conjugated secondary antibody (1:2000) (Amer-
sham) for 1 h. After further washing with PBST, complexes
of antibody-antigen were detected using 3,3V,5,5V-tetramethyl-
benzidine (TMB) substrate (Amersham).
Quantitative real-time PCR
HepG2 cells seeded onto 12-well plate at density of 2 
105 cells per well were treated with recombinant human IFN-
a for the indicated time periods and the indicated dose. Cells
were harvested and total RNA was isolated with TRIzol
reagent (Invitrogen). cDNAwas prepared from 1 Ag of total
RNA using random primers and Superscript II (Invitrogen).
Each PCR was carried out in duplicate in a 20-Al volume
using FastStart DNAMaster SYBR Green I mixture (Roche)
for 5 min at 95 jC for initial denaturing, followed by 40
cycles of 95 jC for 15 s, 56 jC for 15 s, and 72 jC for 30 s in a
lightCycle system (Roche). Detection of the fluorescent
product was set at the last step of each cycle. To determine
the specificity of amplification, melting curve analysis was
applied to all final PCR products after the cycling protocol.
Also, the PCR reactions without the reverse transcription
reaction were performed for each sample to exclude genomic
DNA contamination. The standard curve was prepared with a
serial of dilutions of genomic cDNA from a GAPDH con-
taining plasmid. The forward primer of MyD88 is
5VATGGTGGTGGTTGTCTCTGATG3Vand the reverse prim-
er is 5VGACAGTGATGAACCTCAGGATGC3V. The forward
primer of GAPDH is 5 VGGTATCGTGGAAGGA-
CTCATGAC3V and the reverse primer is 5VATGCCAGTG-
AGCTTCCCGTTCAGC3V. Results were representative of
three independent experiments.
Cell transfection and analysis of HBV proteins
The MyD88 clones (MyD88-6 and MyD88-8) and the
Neo clones were seeded onto 6-well plates at a density of
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transiently transfected with pHBV3.8 (3 Ag) and pcDNA-
CAT (0.5 Ag) plasmids, using the calcium phosphate pre-
cipitation method. At 16 h post-transfection, the medium
was replaced with fresh medium or medium supplemented
with 1000 IU/ml recombinant human IFN-a. After trans-
fection for 1, 2, or 3 days, culture supernatants were
collected and the cells were then lysed. The level of HBsAg
and HBeAg in both supernatants and cell lysates was
measured by standard enzyme-linked immunosorbent assay
(ELISA) (Sino-American Biotech.). Transfection efficiency
was normalized by detecting the activity of chloramphenicol
acetyltransferase (CAT) in cell lysates using CAT ELISA
(Roche). Results represent the average of three independent
experiments performed in duplicate.
Southern blot analysis of viral replicative intermediates
The MyD88-6, MyD88-8, and Neo clones (1  106) were
seeded onto 60-mm dishes and transiently transfected with
pHBV3.8 (10 Ag) and pcDNA-CAT (1.5 Ag). Recombinant
human IFN-a (1000 IU/ml) was added at 16 h post-trans-
fection. After transfection for 48 h, cells were washed twice
with chilled PBS and lysed in 650 Al of lysing buffer (10 mM
Tris–HCl, pH 7.9, 1 mM EDTA, 1% NP-40, 8% sucrose).
After centrifugation at 12000  g for 2 min at 4 jC to
remove nuclei and debris, the supernatants were collected.
An aliquot of each supernatant (50 Al) was saved to assay the
activity of CAT to normalize transfection efficiency. Intra-
cellular core particles were purified from the supernatants,
and HBV replicative intermediate DNA was extracted from
the core particles as described before (Lin et al., 2001). The
normalized viral replicative intermediate DNA samples were
electrophoresed onto 1% agarose gel and blotted onto a
positive nylon membrane (Roche). After fixing at 120 jC for
30 min, the membrane was prehybridized for 6 h at 42 jC in
5  SSC, 5  Denhardt’s solution, 1% SDS, 50% formam-
ide, 0.1 mg/ml salmon sperm DNA, and then hybridized with
full-length HBV DNA probes labeled with [a-32P] dCTP by
hexamer random labeling kit (Roche) under the same con-
dition of prehybridization at 42 jC for 16 h. After stringent
washing at 68 jC, signals were detected by autoradiography.
The experiment was performed thrice and blots were quan-
tified by densitometry.
Northern blot analysis of total or cytoplasmic viral RNAs
The cells (1  106) were transfected with pHBV3.8 (10
Ag) and pcDNA-CAT (1.5 Ag) for 48 h as described above.
Total RNA was extracted directly from transfected cells
using TRIzol reagent. For cytoplasmic RNA, transfected
cells were harvested and lysed by lysing buffer (0.14 M
NaCl, 1.5 mM MgCl2, 10 mM Tris–HCl, pH 8.6, 0.5% NP-
40, 1 mM DTT, 1000 U/ml RNAse inhibitor). After removal
of nuclei by centrifugation, the cytoplasmic RNA in the
supernatants was also extracted using TRIzol reagent. Aftertreatment with DNAse I for 20 min at 37 jC, 10 Ag of total
or cytoplasmic RNA was electrophoresed on 1% formalde-
hyde–agarose gel and then transferred to nylon membranes
(Roche). Hybridization was undertaken as described above
using [a-32P] dCTP-labeled full-length HBV DNA probes.
To normalize the total quantity of RNA loaded on each gel,
blots were stripped and rehybridized with [a-32P] dCTP-
labeled h-actin probes. After autoradiography, blots were
quantified by densitometry. The values of HBV blots were
normalized to the transfection efficiency measured by CAT
ELISA and the corresponding h-actin scanned band values.
Each experiment was performed thrice.
NF-jB activation assays
To measure NF-nB activation, clones of Neo, MyD88-6,
and MyD88-8 seeded onto 12-well plates at density of 2 
105 cells per well were transiently transfected with NF-nB-
dependent luciferase reporter plasmid pNF-nB-Luc (0.3 Ag)
alone, or together with pHBV3.8 (1.0 Ag). Similarly, HepG2
cells were transiently transfected with pNF-nB-Luc (0.3 Ag),
pHBV3.8 (1.0 Ag), pcDNA-MyD88 (1.0 Ag), pcDNA-HBx
(1.0 Ag), and pCI-neo/HBs (1.0 Ag), alone or together as
indicated. In each well, pcDNA-CAT (0.3 Ag) was added as
internal control of transfection efficiency. After transfection
for 18 h, Neo clone and HepG2 cells were kept untreated or
treated with 1000 IU/ml recombinant human IFN-a and
incubated for an additional 6 h. All cells were then lysed and
analyzed with a luciferase assay system (Promega). The
transfection efficiency was monitored using the CAT
ELISA. Data shown were the average of three independent
experiments performed in duplicate.Acknowledgments
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